Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | BAX | Q07812 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9780873 | 0.78 | LTA4H (0.55) | LTA4HTSHRKMT2AKDM4EGLA | |
| SCHEMBL9273369 | 0.76 | TSHR (0.52) | LTA4HTSHRKMT2AKDM4EGLA | |
| SCHEMBL27471024 | 0.76 | LTA4H (0.46) | LTA4HTSHRKMT2AKDM4EGLA | |
| SCHEMBL1451604 | 0.76 | LTA4H (0.46) | LTA4HTSHRKMT2AALDH1A1HPGD | |
| SCHEMBL8702780 | 0.75 | KMT2A (0.41) | LTA4HTSHRKMT2AKDM4EGLA | |
| SCHEMBL10323229 | 0.75 | LTA4H (0.41) | LTA4HTSHRKMT2AKDM4EGLA | |
| SCHEMBL28416915 | 0.74 | TSHR (0.50) | LTA4HTSHRKMT2AKDM4EGLA | |
| SCHEMBL11816942 | 0.74 | LTA4H (0.57) | LTA4HTSHRKMT2AKDM4EGLA | |
| SCHEMBL9275082 | 0.74 | TSHR (0.50) | LTA4HTSHRKMT2AKDM4EGLA | |
| SCHEMBL17273646 | 0.74 | LTA4H (0.73) | LTA4HTSHRKMT2AKDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957073-B1 | MEDICINAL DRUG | OTSUKA PHARMA CO LTD (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-8551999-B2 | Heterocyclic compound and pharmaceutical composition thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2612858-A1 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-8350995-B2 | Optical film, production method of optical film, optically-compensatory film, polarizing plate and liquid crystal display device | FUJIFILM CORPORATION (JP) | 2013-01-08 | — | — | US | disclosed |
| US-20120322807-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-12-20 | — | — | US | disclosed |
| US-20120238750-A1 | AROMATIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-20 | — | — | US | disclosed |
| US-8263599-B2 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8236826-B2 | Diarylether derivatives as antitumor agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-20120184693-A1 | ETHYLENE POLYMER PREPARATION METHOD | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-07-19 | — | — | US | disclosed |
| EP-2207773-B1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMA CO LTD (JP) | 2012-07-11 | — | — | EP | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060115609-A1 | Polarizing plate and display using the same | KONICA MINOLTA OPTO, INC. (JP) | 2006-06-01 | — | — | US | disclosed |
| US-20060078754-A1 | Optical film, polarizing plate and display | KONICA MINOLTA OPTO, INC. (JP) | 2006-04-13 | — | — | US | disclosed |
| WO-2006014012-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-09 | — | — | WO | disclosed |
| US-20050271834-A1 | Cellulose ester film and its manufacturing method, optical film, polarizing plate and liquid crystal display | KONICA MINOLTA OPTO, INC. | 2005-12-08 | — | — | US | disclosed |
| US-20050106334-A1 | Polarizing plate and display | KONICA MINOLTA OPTO, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-20050062193-A1 | Method of producing dispersion | FUJIFILM CORPORATION (JP) | 2005-03-24 | — | — | US | disclosed |
| US-6630973-B1 | Compensatory sheet, ellipsoidal polarizing plate and liquid crystal display. | FUJI PHOTO FILM CO., LTD. (JP) | 2003-10-07 | — | — | US | disclosed |
| EP-1182470-A1 | PHASE CONTRAST PLATE COMPRISING ONE SHEET OF CELLULOSE ESTER FILM CONTAINING AROMATIC COMPOUND | FUJI PHOTO FILM CO., LTD. (JP) | 2002-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238750-A1 | AROMATIC COMPOUND | CBR1, CBR3, CYP1A1 | LTA4H 1506/4885TSHR 1585/4885KMT2A 984/4885 |
| US-20120322807-A1 | STAT3/5 ACTIVATION INHIBITOR | STAT3, JAK2, STAT1 | LTA4H 3917/4885TSHR 643/4885KMT2A 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.